Pull to refresh
Logo
MoonLake's Nanobody drug clears its second Phase 3 test

MoonLake's Nanobody drug clears its second Phase 3 test

New Capabilities

Sonelokimab met its main goal in psoriatic arthritis, adding a second disease to a filing path already moving in hidradenitis suppurativa

Today: IZAR-1 meets all goals in psoriatic arthritis

Overview

MoonLake's experimental drug sonelokimab hit its main goal in a second late-stage trial, this time in psoriatic arthritis. The win moves the small Swiss biotech's Nanobody drug closer to two separate markets.

Psoriatic arthritis is a painful joint disease tied to the skin condition psoriasis. Sonelokimab is built differently from the antibodies doctors use now: it blocks two inflammation signals at once and latches onto albumin to concentrate in swollen tissue. Analysts have said a clean readout could make MoonLake a takeover target worth $8 billion to $10 billion.

Why it matters

A second Phase 3 win moves a novel Nanobody drug toward market and makes MoonLake a likely takeover target for large drugmakers.

Questions about this story

No questions yet — be the first to ask.

Key Indicators

ACR50 met
Primary endpoint, Week 16
The 60 mg dose met a 50% improvement in joint and skin symptoms versus placebo, plus all secondary goals.
~1,500
Patients in IZAR program
The psoriatic arthritis program spans two trials, IZAR-1 and IZAR-2, across the US, Europe and Latin America.
67.2%
Skin-disease response at one year
Share of hidradenitis suppurativa patients hitting HiSCR75 at Week 52 in the separate Phase 3 VELA program.
~$12B
Psoriatic arthritis market, 2025
Estimated global treatment market per Coherent Market Insights, roughly half of it biologic drugs.
$8–10B
Speculated takeover value
Range analysts have floated for MoonLake if late-stage data hold up; the company has not announced a sale.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Play

Exploring all sides of a story is often best achieved with Play.

Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict. Log in Sign Up
Predict 4 ways this could play out. Back the one you believe — contrarian picks score more when a scenario has a resolution date. Log in to play

People Involved

Organizations Involved

Timeline

November 2024 August 2026

4 events Latest: Today
Tap a bar to jump to that date
  1. IZAR-1 meets all goals in psoriatic arthritis

    Today Clinical Trial

    The 60 mg dose meets the ACR50 primary endpoint and every secondary goal at Week 16. Blinded safety matches earlier studies.

  2. One-year skin-disease data hold up

    Clinical Trial

    Week 52 VELA results show 67.2% of hidradenitis suppurativa patients reach HiSCR75 and 33.1% reach HiSCR100, with no new safety signals.

  3. FDA aligns with MoonLake on filing path

    Regulatory

    A positive Type B meeting with the FDA sets up the planned hidradenitis suppurativa application and lifts the stock.

  4. MoonLake launches Phase 3 in psoriatic arthritis

    Clinical Trial

    The two-trial IZAR program begins. IZAR-1 studies biologic-naive patients; IZAR-2 tests harder-to-treat patients against AbbVie's risankizumab.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

April 2023

Merck buys Prometheus Biosciences (2023)

Merck agreed to pay about $10.8 billion for Prometheus Biosciences, a clinical-stage biotech with a late-stage immune-disease antibody. The price was a 75% premium on Prometheus's share price.

Then

The deal closed later in 2023, one of the year's biggest biotech acquisitions.

Now

It set a benchmark for what large drugmakers will pay for de-risked immunology assets to refill pipelines.

Why this matters now

It shows the price range MoonLake could command, and why analysts see a sale as a live outcome once late-stage data land.

2022–2023

UCB's Bimzelx delayed by FDA (2022–2023)

UCB's bimekizumab, the first dual IL-17A and IL-17F antibody, had strong efficacy data but received a Complete Response Letter from the FDA in 2022 tied to a manufacturing inspection, not the drug's benefit.

Then

US approval was pushed to October 2023 for plaque psoriasis.

Now

Bimekizumab went on to win approval in psoriatic arthritis and other conditions and became a growing seller for UCB.

Why this matters now

It is the closest match to sonelokimab's mechanism and a reminder that clean trials do not guarantee an on-time approval.

January 2016

Novartis launches Cosentyx (2016)

Novartis won US approval for secukinumab (Cosentyx) in psoriatic arthritis, the first IL-17A inhibitor cleared for the disease, based on the FUTURE trials.

Then

Cosentyx expanded across psoriasis and spondyloarthritis indications.

Now

It grew into a multibillion-dollar franchise, proving the commercial ceiling for IL-17 drugs in these diseases.

Why this matters now

It marks the market sonelokimab is entering and the incumbent revenue a newer, dual-signal drug would try to take share from.

Sources

(8)